A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (NCT06260163)

🧪 Interventions in This Study

• Guselkumab Subcutaneous (DRUG)
• Guselkumab Intravenous (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (61 Sites)

Showing the first 25 of 61 sites.

• Children's Hospital Oakland — Oakland, California
• Riley Hospital for Children — Indianapolis, Indiana
• NYU Langone Health — Lake Success, New York
• The Kids Research Institute Australia on behalf of the Centre for Child Health Research — Nedlands,
• Mater Hospital Brisbane Inflammatory Bowel Diseases — South Brisbane,
• The Children's Hospital at Westmead — Westmead,
• CHU Charleroi Chimay — Charleroi,
• UZ Gent — Ghent,
• UZ Brussel — Jette,
• UZ Leuven — Leuven,
• Capital Center For Children's health Capital Medical University — Beijing,
• Peking University Third Hospital — Beijing,
• Changzhou No 2 Peoples Hospital — Changzhou,
• The Childrens Hospital Zhejiang University School Of Medicine — Hangzhou,
• Sir Run Run Shaw Hospital Zhejiang University School of Medicine — Hangzhou,
• Ruijin Hospital Shanghai Jiao Tong University — Shanghai,
• Shengjing Hospital Of China Medical University — Shenyang,
• Henan Children's Hospital, Zhengzhou Children's Hospital — Zhengzhou,
• Aarhus Universitetshospital — Aarhus N,
• Hvidovre Hospital — Hvidovre,
• Hospices Civils de Lyon - Groupement Hospitalier Est - Hopital Femme Mere Enfant — Bron,
• Hopital Francois Mitterand — Dijon,
• CHRU Lille — Lille,
• APHP Hopital Robert Debre — Paris,
• CHU Toulouse — Toulouse,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Colitis, Ulcerative

• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Arcadia, California
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Litchfield Park, Arizona
• Determination of the Optimal Treatment Target in Ulcerative Colitis — Ypsilanti, Michigan
• A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis — Kelowna, British Columbia
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis — San Francisco, California

Explore by condition: All Colitis, Ulcerative clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.